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cosmetic outcome was good/excellent in 94% of patients. At 
one year skin toxicity was G1 in 13% of patients, 1 patient 
G2, 1 patient G3; cosmetic outcome was good/excellent in 
93% of patients.After an early evaluation of clinical outcomes 
we have found 12 cases of progression disease, only one 
patient had an In-Breast-Recurrence. 
 
Conclusion: The 3-week course of postoperative radiation 
using VMAT with SIB was well tolerated in acute and early 
late settings. Long-term follow-up data are needed to assess 
late toxicity and clinical outcomes. 
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Purpose or Objective: Breast cancer (BC) could be classified 
into four major molecular subtypes: Luminal-A, Luminal-B, 
triple negative/basal-like, human epidermal growth factor 2 
(HER2) enriched. This classification could be based on 
immunohistochemistry, and may allow the clinicians to 
optimize treatment management. Luminal-A tumors 
represent around 40% of BC and are characterized by: 
estrogen receptor (ER) and/or progesterone receptor (PgR) 
positive, HER2/neu negative, and low Ki-67 proliferative 
index. Early luminal-A tumors tend to have an excellent 
prognosis, with high survival and low recurrence rates. The 
aim of this analysis was to observe Luminal-A outcome from a 
phase 3 trial comparing whole-breast irradiation (WBI) to 
accelerated partial breast irradiation (APBI) using intensity-
modulated radiotherapy (IMRT) technique. 
 
Material and Methods: In the whole trial 520 patients were 
randomized in 1:1 ratio to receive APBI versus WBI after 
breast conserving surgery for early BC. The primary endpoint 
was occurrence of ipsilateral breast tumor recurrence (IBTR); 
the main analysis was by intention-to-treat. This trial was 
registered with ClinicalTrials.gov, number NCT02104895. 
 
Results: Luminal-A patients represented the 61.5% of the 
whole series (151 WBI versus 169 APBI). 5-year event rate 
according to allocated group showed no statistical difference 
in terms of IBTR (p=0.53). One case (0.9%) versus two cases 
(1.7%) were observed in the WBI and APBI arms, respectively. 
Survival events occurrences and IBTR curve are summarized 
in the Figures. 
 
 
 
 
Conclusion: We observed a very low 5-year rate of IBTR for 
Luminal-A patients treated with APBI. Although these results 
should be confirmed at a longer follow up time, this approach 
should be considered for this subset of early BC patients. 
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Purpose or Objective: To evaluate toxicity in breast cancer 
patients treated with anthracycline and taxane based 
chemotherapy and whole breast hypofractionated 
radiotherapy, and to identify the risk factors for toxicity. 
 
Material and Methods: From April 2009 to December 2014, 
540 patients received radiotherapy after breast conservative 
surgery (BCS). The dose was 42.4 Gy in 16 daily fractions, 
2.65 Gy per fraction. The boost to the tumor bed was 
administered only in grade 3 patients and in patients with 
close or positive margins. Acute and late toxicity were 
prospectively assessed during and after radiotherapy 
according to RTOG scale. The impact of patients clinical 
characteristics and dose inhomogeneities on the occurrence 
of an higher level of toxicity has been also evaluated by 
univariate and multivariate analysis. 
 
Results: One hundred and nineteen patients received 
chemotherapy. Sixty-one patients (11.3%) underwent 
trastuzumab therapy and four hundred and forty-one (81.6%) 
hormonotherapy. The mean age was 74 (range 46-91 yrs). 
Forty seven (8.7%) and two hundred fifty eight (47.5%) 
patients were affected by diabetes mellitus and 
hypertension, respectively. G1 and G2/G3 acute skin toxicity 
were 53.7% and 28.5% in patients received chemotherapy and 
63.2% and 18.5% in patients who did not receive it, 
respectively. No significant difference (p=0.092) was find 
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between the two groups of treatment. The boost 
administration (p< 0.01), the breast volume (p 0.04), dose 
inhomogeneities (p<0.01) and boost volume (0.04) were 
found to be statistically significant as concerns the 
occurrence of acute skin reaction at the univariate analysis; 
the boost administration (p< 0.01), and hormonotherapy (p 
0.01) at multivariate analysis. Other clinical factors such as 
diabetes or hypertension were not correlated with the 
development of acute skin reaction. G1 and G2/G3 late 
fibrosis were 15.3% and 8.1% in patients received 
chemotherapy and 12.3% and 3.1% in patients who did not 
receive it, with a significant difference (p=0.045) between 
the two groups. Diabetes (p 0.04) and boost administration (p 
<0.01) were also found to be statistically significant on the 
occurrence of late fibrosis, but a multivariate analysis 
adjusted also for clinical tumour characteristics did not show 
any factors correlated to late fibrosis . 
 
Conclusion: The results of our study, according to the large 
randomized trials, confirmed that hypofractionated whole 
breast irradiation is safe, even in patients treated with 
chemotherapy. Chemotherapy didn’t impact on acute toxicity 
but only on late toxicity; however the percentage of G2-G3 
fibrosis is low (8.1 vs 3.1%). Our study confirmed an increase 
of acute and late toxicity in patients who received additional 
boost.  
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Purpose or Objective: The effect of radiotherapy (RT) on the 
outcome of autologous reconstruction after mastectomy for 
breast cancer is unclear. Advances in technique such as the 
deep inferior epigastric artery perforator (DIEP) flap and 
IMRT may affect the complication rate. We seek to 
retrospectively evaluate the outcomes after flap 
reconstruction at our institution with a focus on radiotherapy 
variables. 
 
Material and Methods: Patients receiving flap reconstruction 
after mastectomy at our institution from 2003-2014 were 
identified in a chart review. Analysis was limited to patients 
with a coded cancer status and who returned for at least one 
follow up visit. The outcome variables analyzed were flap 
loss or any complication (loss, ischemia, hematoma, 
infection). Descriptive data analyzed included age, tumor 
stage, flap type, chemotherapy, and radiation. RT specific 
variables included radiation at an academic medical center vs 
independent radiotherapy facility, 3D-CRT vs IMRT, and 
whether radiation was directed to the internal mammary (IM) 
region. Analyses was on a per-flap basis rather than per 
patient. Statistics were done in SPSS using logistic regression. 
Two prognostic models were generated. The first included all 
patients and analyzed age, stage, flap type, chemotherapy, 
and radiation therapy. The second model included only those 
receiving radiation therapy and included significant factors 
from the first model and the RT variables discussed above.  
 
Results: 291 patients receiving 402 flap procedures met 
inclusion criteria. Mean age was 47.2 years with median 
follow up of 339 days. 93 (21.2%) had transverse rectus 
abdominis (TRAM) flaps, 178 (40.6%) had muscle sparing 
TRAM flaps, and 121 (27.6%) had DIEP flaps. 128 (29.2%) flaps 
were done after mastectomy for benign histology; 62 (14.2%) 
were for DCIS/ LCIS, 69 (15.8%) were for stage I, 88 (20.1%) 
were for stage II, 52 (11.9%) were for stage III, and 3 (0.7%) 
were for stage IV disease. 146 (33.3%) received RT and 187 
(42.7%) received neoadjuvant chemotherapy. Of those 
receiving RT, 42 (28.7%) received 3D-CRT, 38 (26.0%) 
received IMRT, and 66 (44.5%) had unknown RT technique. 28 
(6.9%) flaps failed and 64 (15.9%) flaps had a complication. 
The first model, which included all patients, identified 
increasing cancer stage (p=0.03) as the most important 
variable for flap loss with a hazard ratio of 3.4 for DCIS/LCIS, 
2.1 for stage I, 7.3 for stage II, and 1.8 for stage III compared 
to benign pathology. Age was the only variable associated 
with increased overall complications. In the second model, 
location of RT, RT technique, and IM directed radiation were 
not significant predictors of flap loss or complications. 
 
Conclusion: Cancer stage and age are important predictors 
for flap failure and complications. Use of chest wall radiation 
therapy was not a significant predictor of flap failure.  
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Purpose or Objective: Correct GTV delineation is the basis 
for accurate radiotherapy treatment. It is important to 
determine which imaging modality (CT, MRI or FDG-PET) 
results in most accurate GTV delineation. For clinical 
assessment, both GTV delineations and target volumes 
adjusted for delineation inaccuracies were compared with 
histopathology. 
 
Material and Methods: Twenty-seven patients with a 
laryngeal or hypopharyngeal tumor (T3/T4) were imaged with 
CT, MRI and FDG-PET followed by laryngectomy. Imaging was 
performed in radiotherapy positioning mask. GTV was 
delineated in consensus by three observers on CT and MRI, 
while a semi-automatic delineation was performed on FDG-
PET using an intensity based threshold method. The true 
tumor volume was delineated by one pathologist on whole-
mount histopathological sections. These slides were digitized 
and the specimen was reconstructed in 3-dimensions. The 
tumor contours were non-rigidly transferred to the imaging 
acquired before tumor resection.  
To cover 95% of the outer contour of all tumors, modality 
dependent target margins were derived and added to the 
GTV (Fig. 1a). GTVs and target volumes were compared 
between the modalities. 
 
 
 
Results: The median tumor volume delineated on pathology 
was 10.5 ml (range: 3.4 ml – 68.6 ml). Median GTVs 
delineated on CT, MRI and PET were 17.5 ml, 15.2 ml and 
14.8 ml, respectively. None of the GTVs fully covered the 
pathological tumor volume with a median tumor coverage of 
93%, 90% and 87%. In several cases, the position of cartilage 
invasion was not recognized, which contributed to missing 
tumor volume.  
